Klacid Paediatric Suspension is indicated for the treatment of infections caused by susceptible organisms. Indications include
• Lower respiratory tract infections
• Upper respiratory tract infections
• Skin and skin structure infections
• Acute otitis media
Klacid Paediatric Suspension is usually active against the following organisms in vitro:
Gram-positive Bacteria: Staphylococcus aureus (methicillin susceptible); Streptococcus pyogenes (Group A beta-haemolytic streptococci); alpha-haemolytic streptococci (viridans group); Streptococcus (Diplococcus) pneumoniae; Streptococcus agalactiae; Listeria monocytogenes.
Gram-negative Bacteria: Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella (Branhamella) catarrhalis, Neisseria gonorrhoeae; Legionella pneumophila, Bordetella pertussis, Helicobacter pylori; Campylobacter jejuni.
Mycoplasma: Mycoplasma pneumoniae; Ureaplasma urealyticum.
Other Organisms: Chlamydia trachomatis; Mycobacterium avium; Mycobacterium leprae; Chlamydia pneumoniae.
Anaerobes: Macrolide-susceptible Bacteroides fragilis; Clostridium perfringens; Peptococcus species; Peptostreptococcus species; Propionibacterium acnes.
Klacid Paediatric Suspension has bactericidal activity against several bacterial strains. These organisms include Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Moraxella (Branhamella) catarrhalis, Neisseria gonorrhoeae, Helicobacter pylori and Campylobacter species.
The activity of clarithromycin against Helicobacter pylori is greater at neutral pH than at acid pH.
Clarithromycin suspension is indicated in children, 6 months to 12 years.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
|